Latest Content

After receiving a stage 1 lung cancer diagnosis, Carolyn Rothfeld underwent robotic surgery to remove part of her lung and is back to her exercise routine nine months later.

After breast cancer, one survivor reflects on reclaiming her life by remodeling her kitchen and embracing the freedom to focus on something beyond cancer.

High-risk multiple myeloma is identified through bone marrow testing and can help guide treatment decisions, from combination therapy to clinical trials.

Diagnosed with stage 1 lung cancer at 40, Gillian Ryan shares the overwhelming guilt she felt about bringing cancer into her family’s life.

Learn how Talvey plus Tecvayli cut the risk of myeloma progression or death by 89%, how the combination is given and what it may mean for daily life.

Dr. Mark Zhao explains how minimally invasive techniques preserve function, speed recovery and why patients should not wait years to raise bowel symptoms with their doctor.

Six years after follicular lymphoma treatment, a follow-up CT scan brought encouraging news—but the fear of recurrence and uncertainty still linger.

Luciana Lopes Manfredini, of Einstein Hospital Israelita in São Paulo, Brazil, developed a triage scale for emergency cancer patients now being adopted across North and Latin America.

Melanie Diaz, DNP, NP-C, OCN, of St. Francis Cancer Institute, blends firm accountability with deep empathy to keep cancer patients engaged and empowered throughout treatment.

The 10-3 vote came during a discussion in which the limitations of TIL therapy, the only approved option for this group of patients, were raised repeatedly.

The FDA approved Pluvicto with hormone therapy for PSMA-positive metastatic prostate cancer, helping delay disease progression in patients.

Patients with advanced biliary tract cancer lived longer on Imfinzi (durvalumab) plus chemotherapy than on chemotherapy alone, according to four-year follow-up data from the phase 3 TOPAZ-1 trial.

Tafinlar plus Mekinist extended progression-free survival to 12.8 months vs. 3.7 months with placebo in BRAF V600E-positive thyroid cancer.